Company overview
Artios Pharma is a clinical-stage biopharmaceutical company developing first-in-class DNA Damage Response (DDR) inhibitors for hard-to-treat cancers. Its pipeline includes ATR inhibitor alnodesertib in clinical trials for pancreatic and colorectal cancers, DNA polymerase theta (Polθ) inhibitor ART6043 advancing to phase 2 for BRCA-mutant breast cancer, and preclinical DDRi-ADC candidates. The company leverages its DcoDeR platform and partnerships to target DDR pathways, overcoming resistance to therapies like PARP inhibitors.
DNA Damage Response is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include artios pharma, dna damage response, ddr inhibitors, atr inhibitor, polθ inhibitor, cancer therapeutics.
Structured facts
- Website
- https://www.artios.com
- Markets served
- United States & Americas
- Keywords
- artios pharma, dna damage response, ddr inhibitors, atr inhibitor, polθ inhibitor, cancer therapeutics
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What is Artios Pharma's main therapeutic focus?
- Artios specializes in DNA Damage Response (DDR) inhibitors targeting cancer cells' DNA repair mechanisms, including ATR inhibitor alnodesertib and Polθ inhibitor ART6043 for solid tumors like pancreatic, colorectal, and breast cancers.
- What stage are Artios' lead programs in?
- Alnodesertib (ATR inhibitor) is in clinical trials, expanding to second-line pancreatic and third-line colorectal cancers; ART6043 (Polθ inhibitor) showed early data and plans phase 2 in BRCA-mutant breast cancer; preclinical DDRi-ADCs are in development.
- Where is Artios Pharma located and what are its key partnerships?
- Headquartered in Cambridge, UK, and New York, USA, with a partnership with Cancer Research Technology (CRT) of Cancer Research UK for DDR programs.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
